Literature DB >> 16702798

Eosinophilic pancreatic infiltration as a manifestation of lung carcinoma.

Walid R Saliba1, Muralee Dharan, Naiel Bisharat, Mazen Elias.   

Abstract

A 68-year-old man reported upper abdominal pain during the previous 3 months that worsened in the last 2 days. He had a history of lung squamous cell carcinoma for which he underwent right lung lobectomy 3 years earlier. Preliminary blood tests showed leucocytosis with marked eosinophilia. No evidence of recurrent malignancy was detected, but computed tomography scan of the abdomen revealed an enlarged and edematous pancreas with hyperemia and infiltration of the peripancreatic fat. Fine needle aspiration from the lesion revealed inflammatory infiltration predominantly composed of eosinophils. The diagnosis of eosinophilic pancreatitis was suggested and the patient was placed on prednisone, but without any clinical or laboratory improvement. Two months later, the patient developed severe dyspnea, chylothorax, and acute renal failure. Cytologic studies of the pleural fluid revealed malignant cells from recurrent lung squamous cell carcinoma. The disease course was characterized by rapid deterioration and a fatal outcome. To the authors' knowledge, eosinophilic pancreatic infiltration as a manifestation of lung carcinoma has not been previously reported.

Entities:  

Mesh:

Year:  2006        PMID: 16702798     DOI: 10.1097/00000441-200605000-00008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Hypereosinophilia in Solid Tumors-Case Report and Clinical Review.

Authors:  Ewa Zalewska; Łukasz Obołończyk; Krzysztof Sworczak
Journal:  Front Oncol       Date:  2021-03-24       Impact factor: 6.244

2.  Tumor-associated eosinophilia in a patient with EGFR-positive, MET-amplified lung adenocarcinoma refractory to targeted therapy: a case report and review of literature.

Authors:  Nan Geng; Wenxia Hu; Hui Ge; Shaonan Xie; Cuimin Ding
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.